An array of pharmaceutical pills with the company's logo on the bottle. Eli Lilly and Company (NYSE:LLY) is a global leader in pharmaceuticals, specializing in diabetes care. Since introducing the ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires.In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

Eli Lilly (LLY) stock gains as Goldman Sachs upgrades it to Buy from Neutral citing the company's leadership position in the ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE:LLY) has introduced its diabetes and weight-loss drug Mounjaro in India, ahead of its competitor Novo Nordisk (NYSE:NVO). This comes as ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.